First
Name
Cima_First in vivo.pdf
Size
1.44 MB
Format
Adobe PDF
Checksum (MD5)
c4847b7dd0a55a2c5f273b07cdeed274
Author(s)
Calligaris, David
Methuku, Kashi Reddy
Poe, MichaelM.
Francois, Jessica Pierre
Tranghese, Frank
Changelian, Armen
Sieghart, Werner
Ernst, Margot
Pomeranz Krummel, Daniel A.
Cook, M. James
Date Issued
June 2016
Journal
Journal of Biomedical Nanotechnology
Publisher
American Scientific Publishers
Citation
Jonas, Oliver et al. “First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development.” Journal of Biomedical Nanotechnology 12, 6 (June 2016): 1297–1302 © 2016 American Scientific Publishers
Version
Author's final manuscript
Abstract
Medulloblastoma is the most common childhood malignant brain tumor. The most lethal medulloblastoma subtype exhibits a high expression of the GABA A receptor α5 subunit gene and MYC amplification. New benzodiazepines have been synthesized to function asα5-GABA A receptor ligands. To compare their efficacy with that of standard-of-care treatments, we have employed a newly developed microscale implantable device that allows for high-throughput localized intratumor drug delivery and efficacy testing. Microdoses of each drug were delivered into small distinct regions of tumors, as confirmed by tissue mass spectrometry, and the local drug effect was determined by immunohistochemistry. We have identified a benzodiazepine derivative, KRM-II-08, as a new potent inhibitor in several α5-GABA A receptor expressing tumor models. This is the first instance of in vivo testing of several benzodiazepine derivatives and standard chemotherapeutic drugs within the same tumor. Obtaining high-throughput drug efficacy data within a native tumor microenvironment as detailed herein, prior to pharmacological optimization for bioavailability or safety and without systemic exposure or toxicity, may allow for rapid prioritization of drug candidates for further pharmacological optimization.
MIT Department
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1166/JBN.2016.2262
